CERS

Cerus Corporation develops and supplies technologies for pathogen reduction in blood components, focusing on safeguarding the global blood supply. Its primary product, the INTERCEPT Blood System, is designed for platelets, plasma, and cryoprecipitated fibrinogen, and is approved for use in both the U.S. and Europe. The company serves blood centers and hospitals, providing solutions that enhance the safety of blood transfusions for patients. Headquartered in Concord, California, Cerus operates in the medical technology sector, specifically within blood safety and transfusion medicine.